1. Welage L S，Berardi R R. Evaluation of omeprazole，lansoprazole，pantoprazole，and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc，2000，40（1）：52-62

2. Saltiel E，Fask A. Prevalence of potential proton-pump inhibitor drug interactions：A retrospective review of prescriptions in community pharmacies. Clin Ther，1999：21（10）：1812-1819

3. Huber R，Hartmann M，Bliesath H，et al. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther，1996，34：S7-S16

4. Zech K，Steinijans VW，Huber R，et al. Pharmacokinetics and drug interactions-relevant factors for the choice of a drug. Int J Clin Pharmacol Ther，1996，34（Suppl）：S3-S6

5. 邵明立.国家基本药物（西药）.第2版.北京：人民卫生出版社，2002：477

6. Horai TY. Cytochrome P450 and the metabolism of proton pump inhibitor emphasis on rabeprazole. Aliment Pharmacol Ther，1999，13（Suppl 3）：27

7. Li XQ，Tommy B，Ahlstrom M，et al. Comparison of inhibitory effects of the proton pump inbibiting drugs omeprazole，esomprazole，lansoprazole，pantoprazole，rabeprazole on human cytochrome P450 activities. Drug Metab Dispos，2004，32（8）：821

8. Omari TI，Haslam RR，Lundborg P，Davidson GP. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux. J Pediatr Gastroenterol Nutr. 2007，44（1）：41-44

9. Moore DJ，Tao BS，Lines DR，et al. Double-blind placebocontrolled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr，2003，143（2）：219-223

10. Khoshoo V，Dhume P. Clinical response to 2 dosing regimens of lansoprazole in infants with gastroesophageal reflux. J Pediatr Gastroenterol Nutr，2008，46（3）：352-354

11. Orenstein SR，Hassall E，Furmaga-Jablonska W，et al. Multicenter，double-blind，randomized，placebocontrolled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr，2009，154（4）：514-520

12. Winter H，Kum-Nji P，Mahomedy SH，et al. Efficacy and safety of pantoprazole delayedreleasegranules for oral suspension in a placebo-controlled treatment-withdrawalstudy in infants 1-11 months old with symptomatic GERD. J Pediatr Gastroenterol Nutr，2010，50 （6）：609-618

13. Tolia V，Bishop PR，Tsou VM，et al. Multicenter，randomized，double-blind study comparing 10，20 and 40 mg pantoprazole inchildren（5-11 years）with symptomatic gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr，2006，42（4）：384-391

14. Gilger MA，Tolia V，Vandenplas Y，et al. Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr，2008，46（5）：524-533

15. Boccia G，Manguso F，Miele E，et al. Maintenance therapy for erosive esophagitis in children after healing by omeprazole：is it advisable？ Am J Gastroenterol，2007，102（6）：1291-1297

16. Borrelli O，Rea P，Bueno de MM，et al. Efficacy of combined administration of an alginate formulation（Gaviscon）and lansoprazole for children with gastroesophageal reflux disease. Ital J Pediatr，2002，28（4）：304-309

17. Cucchiara S，Minella R，Iervolino C，et al. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Arch Dis Child，1993，69（6）：655-659

18. Tsou VM，Baker R，Book L，et al. 326 Study Group. Multicenter，randomized，doubleblind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents（12 to 16 years of age）with gastroesopha- geal reflux disease（GERD）.Clin Pediatr（Phila），2006，45：741-749

19. Gold BD，Gunasekaran T，Tolia V，et al. Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr，2007，45 （5）：520-529

20. 《中华儿科杂志》编辑委员会，中华医学会儿科学分会消化学组.小儿胃食管反流病诊断治疗方案（试行）.中华儿科杂志，2006，44（2）：96

21. Frederiksen MC. Physiologic changes in pregnancy and their effect on drug disposition. Semin Perinatol，2001，25（3）：120-123

22. Dawes M，Chowienczyk PJ. Drugs in pregnancy. Pharmacokinetics in pregnancy. Best Pract Res Clin Obstet Gynaecol，2001，15：819-826

23. 黄亮，陈力，林芸竹，等.妊娠期药动学变化及其研究进展.中国药房，2007，18（31）：2462-2464

24. And erson GD. Pregnancy-induced changes in pharmacokinetics：a mechanistic-based approach. Clin Pharmacokinet，2005，44：989-1008

25. Benet LZ，Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther，2002，71（3）：115

26. Nakai A，Sekiya I，Oya A，et al. Assessment of the hepatic arterial and portal venous blood flows during pregnancy with Doppler ultrasonography. A rch Gynecol Obstet，2002，266 （1）：25-29

27. 马玉燕，马丽娟，高凌雪.妊娠及哺乳期药物代谢特点.中国实用妇科与产科杂志，2008，24（6）：462-464

28. Moraes-Filho J，Cecconello I，Gama-Rodrigues J，et al. Brazilian consensus on gastroesophageal reflux disease：proposals for assessment，classification，and management. Am J Gastroenterol， 2002，97（2）：241-248

29. Katz PO，Castell DO. Gastroesophageal reflux disease during pregnancy. Gastroenterol Clin North Am，1998，27（1）：153-167

30. Charan M，Katz PO. Gastroesophageal reflux disease in pregnancy. Curr Treat Options Gastroenterol，2001，4（1）：73-81

31. Berardi RR. Proton pump inhibition. An effective，safe approach to GERD management. Postgrad Med，2001，Spec No：24-35

32. Kallen B. Delivery outcome after the use of acid -suppressing drugs in early pregnancy with special reference to omeprazole. Br J Obstet Gynaecol，1998，105（8）：877-881

33. Nielsen GL，Sorensen HT，Thulstrup AM，et al. The safety of proton pump inhibit ors in pregnancy. Aliment Pharmacol Ther，1999，13（8）：1085-1089

34. Lindhoff-LastE，Bauersachs R. Heparin- induced thrombocytopenia-alternative anticoagulation in pregnancy and lactation. Sem in Thromb Hemost，2002，28：439-446

35. Ambros L，Montoya L，Kreil V，et al. Pharmacokinetics of erythromycin in nonlactating and lactating goats after intravenous and intramuscular administration. J Vet Pharmacol Ther，2007，30：80-85

36. Newport DJ，Calamaras MR，DeV ane CL，et al. Atypical anti-psychotic administration during late pregnancy：placental passage and obstetrical outcomes. Am J Psychiatry，2007，164：1214-1220

37. Sharon Gardiner. Drug Safety in Lactation. 2001，http://www.medsafe.govt.nz/profs/ puarticles/lactation.htm

38. Nava-Ocampo AA，Velázquez-Armenta EY，Han JY，Koren G. Use of proton pump inhibitors during pregnancy and breastfeeding. Can Fam Physician，2006. 52：853-854

39. 金惠铭.病理生理学.第6版.北京：人民卫生出版社，2006

40. 王广基.药物代谢动力学.北京：化学工业出版社，2006：181-182

41. 骆泽宇.奥美拉唑的临床合理应用及不良反应.现代中西医结合杂志，2005，14（24）：3314-3315

42. 张晓东，方敬爱，武明虎.奥美拉唑导致间质性肾炎的临床分析.中国中西医结合肾病杂志，2006，7（9）：543

43. 王光华，裴艳香.埃索美拉唑相关药物性肝损害.药物不良反应杂志，2008，10（2）：85，103